Chronic Myeloid Leukemia
Peripheral blood progenitor cells mobilize after response to leukemia therapy
Published in Cancer Weekly, August 30th, 2005
"Imatinib mesylate (IM) was introduced in chronic myeloid leukemia (CML) treatment in the late 1990s and substantially changed the therapeutic approach to the disease, by inducing complete cytogenetic response (CCR) in approximately 60% of cases. Nevertheless, some concerns exist about the duration of response to treatment and the onset of resistance to IM," researchers in Italy report.
"Twenty-five chronic-phase CML patients in stable CCR (>6 months) treated for at least 1 year with IM at the standard dose (400 mg/day) were mobilized with recombinant human...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2005-08-30)
More Articles from Cancer Weekly
- Colorectal Cancer
Genomic aberrations in MSH2 and MLH1 frequently occurred in Chinese CRC - Leukemia
Periconceptional vitamin use reduced leukemia risk in children with DS - Malignant Melanoma
Phx-3 induces antitumor activity against malignant melanoma cells - Ovarian Cancer
PCR used to diagnose peritoneal tuberculosis mimicking ovarian cancer - Acute Care
Clinical pathway to improve care of nearly dying oncology inpatients assessed - Adenocarcinoma
Transformed bronchioalveolar stem cells give rise to adenocarcinoma - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
